- Home
- THG vs BBIO Comparison
THG vs BBIO Comparison
Compare THG & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THG
- BBIO
- Stock Information
- Founded
- THG 1852
- BBIO 2015
- Country
- THG United States
- BBIO United States
- Employees
- THG N/A
- BBIO N/A
- Industry
- THG Property-Casualty Insurers
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- THG Finance
- BBIO Health Care
- Exchange
- THG Nasdaq
- BBIO Nasdaq
- Market Cap
- THG 6.1B
- BBIO 6.7B
- IPO Year
- THG 1995
- BBIO 2019
- Fundamental
- Price
- THG $176.15
- BBIO $34.25
- Analyst Decision
- THG Buy
- BBIO Strong Buy
- Analyst Count
- THG 9
- BBIO 12
- Target Price
- THG $179.00
- BBIO $57.09
- AVG Volume (30 Days)
- THG 218.3K
- BBIO 2.9M
- Earning Date
- THG 04-30-2025
- BBIO 04-29-2025
- Dividend Yield
- THG 2.05%
- BBIO N/A
- EPS Growth
- THG 167.70
- BBIO N/A
- EPS
- THG 12.02
- BBIO N/A
- Revenue
- THG $6,289,500,000.00
- BBIO $127,415,000.00
- Revenue This Year
- THG $5.52
- BBIO $89.10
- Revenue Next Year
- THG $5.73
- BBIO $57.07
- P/E Ratio
- THG $14.66
- BBIO N/A
- Revenue Growth
- THG 3.09
- BBIO N/A
- 52 Week Low
- THG $119.66
- BBIO $21.62
- 52 Week High
- THG $176.71
- BBIO $39.54
- Technical
- Relative Strength Index (RSI)
- THG 66.56
- BBIO 50.58
- Support Level
- THG $163.48
- BBIO $31.77
- Resistance Level
- THG $170.80
- BBIO $33.93
- Average True Range (ATR)
- THG 3.10
- BBIO 1.28
- MACD
- THG 0.82
- BBIO -0.09
- Stochastic Oscillator
- THG 95.99
- BBIO 57.14
About THG Hanover Insurance Group Inc
The Hanover Insurance Group Inc is a holding company whose primary business is offering property and casualty insurance products and services. The company markets itself through independent agents and brokers in the United States while conducting business internationally through a wholly owned subsidiary, Chaucer Holdings Limited, domiciled in the United Kingdom. The company conducts business operations through four operating segments: Core Commercial, Specialty, Personal Lines, and Other. The company operates an investment portfolio that is exposed to fixed-income securities.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.